Navigation Links
TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Date:6/21/2010

PLYMOUTH, Mich. and BATON ROUGE, La., June 21 /PRNewswire/ -- Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease. Under the terms of the agreement, TransGenRx will coordinate production of protein-based therapies for a range of research needs using a proprietary expression system.

Researchers at Esperion are working to develop novel therapies to treat cardio-metabolic disease including therapies based on HDL, the body's "good" cholesterol, which has been shown to play an important role in lipid management. The company's development platform includes therapies designed to mimic or enhance the function of HDL in managing and removing cholesterol and other lipids from atherosclerotic plaques. Researchers at Esperion have initiated preclinical and clinical research related to a variety of pathways for better lipid regulation to treat the full spectrum of cardio-metabolic diseases, from early risk factors to acute coronary syndromes and atherosclerosis.

"While HDL continues to show great promise in the treatment of cardiovascular disease, there have been significant challenges in the development of protein-based drug therapies. By working with the outstanding research and technology team at TransGenRx, we are positioned to access one of the most advanced, cost-effective protein expression technologies in the world to supply the protein-based therapies we will use in our research," said Roger Newton, Ph.D., President and CEO of
'/>"/>

SOURCE Esperion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Althea Technologies Acquires Altus Pharmaceuticals(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations.
2. California Natural Products Unveils CalNaturale(TM) Svelte(TM) All-Natural Sustained Energy Protein Drink
3. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
7. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
8. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
9. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
10. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
11. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, ... is scheduled to present a corporate overview and update at ... Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 ... New York . A live ... investor relations section of Arena,s website at www.arenapharm.com . ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... N.J., March 8, 2012  Janssen Research & Development, ... Phase 3 study of ZYTIGA® (abiraterone acetate) plus ... symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) ... Study COU-AA-302 is an international, randomized, double-blind, placebo ...
... AMSTERDAM, March 8, 2012  Leading events organiser UBM Live ... announced an addition to the CPhI Japan events line-up ... Sight Exhibition Centre from 21-23 March, 2012. The Pharmatech ... technology for the Pharma, biopharma, veterinary and medical industries, ...
Cached Medicine Technology:Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 3Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 4Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 5Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 6New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
(Date:11/26/2014)... 26, 2014 Sonru, the video interviewing ... Chief Operating Officer and Chief Marketing Officer, in addition ... , Jeff Jones has been appointed as Chief ... takes the role of Chief Marketing Officer. , Mr ... whose 25-year career includes senior roles with The Walt ...
(Date:11/26/2014)... November 26, 2014 Call 866-997-4948 (Us-Canada ... or email the details on sales(at)researchmoz(dot)us , Researchmoz.us ... drug discovery market 2014" with deep study of the ... result of high blood sugar. The global glucose monitoring ... to the growing number of diabetics in the world. ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 For those with ... new LES MILLS BODYPUMP™ classes at the University ... the workout they've been looking for. The 45- 60 minute ... Anschutz Health and Wellness Center fitness club memberships. , LES ... workouts are fast-paced and are aimed at fast results ...
(Date:11/26/2014)... 26, 2014 Sonoran Vein and ... received the Distinguished Preceptorship Award from The ... role in the advancement of nurse practitioners. The ... individual who had made a significant contribution toward ... American Association of Nurse Practitioners (AANP) is the ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2
... an efficient, effective way to analyze wounds from bullets and ... the March issue of Radiology . "The ... care and aid in both military and civilian forensic investigations," ... from the Uniformed Services University in Bethesda, Md. U.S. ...
... Extremely obese people had a significantly greater chance of dying ... that became a pandemic last winter, a new study reports. ... with H1N1 flu during the first four months of 2009 ... three-fold increased risk for death. Extreme obesity is defined ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, Jan. ... the risk of autism in the second child, new research ... within a year of their older sibling. Babies conceived within ... their older sibling were also at a heightened risk of ...
... HealthDay Reporter , MONDAY, Jan. 10 (HealthDay News) -- Widespread ... a 5 percent drop in available nursing home beds across ... research reveals. "The country,s minority population is aging at ... lead author Zhanlian Feng, an assistant professor of community health ...
... is well known that pain is a highly subjective experience. ... depending on distractions and mood. A paper in the ... cautionary note on measuring perceived pain in research. There ... symptoms other than pain, but because of the subjectivity in ...
... report a gene therapy strategy that improves the condition ... Beta Thalassemia. The gene correction involves using unfertilized ... embryonic stem cell lines. Some of these stem cell ... thus be used for transplantation-based treatments of the same ...
Cached Medicine News:Health News:CT helps identify bullet trajectories 2Health News:Closely Spaced Pregnancies Might Up Autism Risk: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 3Health News:Does it hurt? 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: